Article
Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.
Oncotarget - 1 Nov 2016
Kawaguchi Kei, Murakami Takashi, Chmielowski Bartosz, Igarashi Kentaro, Kiyuna Tasuku, Unno Michiaki, Nelson Scott D, Russell Tara A, Dry Sarah M, Li Yunfeng, Eilber Fritz C, Hoffman Robert M
Abstract excerpt
Melanoma is a recalcitrant disease. The present study used a patient-derived orthotopic xenograft (PDOX) model of melanoma to test sensitivity to three molecularly-targeted drugs and one standard chemotherapeutic. A BRAF-V600E-mutant melanoma obtained from the right chest wall of a patient was grown orthotopically in the right chest wall of nude mice to establish a PDOX model. Two weeks after implantation, 50...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.